24/7 Market News Publishes Report on how Kraig Biocraft's BAM-1 Spider Silk Hybrid Production Affects Spider Silk Market
Kraig Biocraft Laboratories (OTCQB: KBLB) has initiated the production phase for its BAM-1 recombinant spider silk hybrids.
This move follows successful spring production trials, marking the company's largest single batch of spider silk production to date.
The company's CEO, Kim Thompson, emphasized the significance of this milestone, aiming for a metric ton of spider silk production in 2024.
This development is expected to accelerate Kraig Biocraft's 2024 production schedule and cement its position in the commercial spider silk market.
- Kraig Biocraft Laboratories has launched production of BAM-1 recombinant spider silk hybrids.
- The spring production trials were successful, demonstrating effective team, technology, and facilities.
- This is the largest single batch of spider silk production in the company's history.
- The company aims to produce a metric ton of spider silk in 2024, accelerating its production schedule.
- The press release does not provide specific financial data or revenue projections.
- Potential risks associated with scaling up production are not addressed.
- No information on potential market competition or challenges is provided.
- The PR lacks details on cost structures or potential profitability margins.
Denver, Colorado--(Newsfile Corp. - June 5, 2024) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, today publishes a news report on Kraig Biocraft Laboratories (OTCQB: KBLB) launching the production phase for its BAM-1 recombinant spider silk hybrids.
To read the full article on 247marketnews.com, please click here.
Kraig Biocraft Laboratories (OTCQB: KBLB)
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10481/211781_kraigbiocraftlogo.jpg
Kraig Biocraft Laboratories (OTCQB: KBLB) is pioneering the production of genetically bioengineered spider silk, using silkworms modified to spin spider silk cocoons that can be harvested in commercial quantities.
The Company recently reported that, by launching its BAM-1 recombinant spider silk hybrids production, it's accelerating its 2024 production schedule, following the resounding successes of its spring production trials.
Spring Trial Spider Silk Cocoons
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10481/211781_kraigbiocraftimage.jpg
This production cycle serves as Kraig's first transition of true production hybrids to the manufacturing environment and is the largest single batch of spider silk production in the Company's history.
"This successful launch of the BAM-1 hybrids is the result of more than a year of focused development by our team. The spring production trials demonstrated that we have brought together the right team, the right technology, and the right facilities to make 2024 a breakout year for the commercialization of spider silk," said Founder and CEO of Kraig Labs, Kim Thompson. "This cycle puts us securely on the path to reaching our first production milestone of a metric ton of spider silk."
To continue reading full article on 247marketnews.com, please click here.
About 24/7 Market News
24/7 MarketNews is a leading market news platform for public companies. As a pioneer in digital media, we are dedicated to the swift distribution of financial market news and information. We take great pride in creating innovative public relations campaigns that help our clients reach their target audience.
Please go to www.247marketnews.com for further information.
24/7 MARKET NEWS, INC Disclaimer
Please click here or https://www.247marketnews.com/disclaimer/ for disclosure information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, the popularity and/or competitive success of the Company's acquired football and other sports teams, the Company's ability to attract players and staff for acquired clubs, unsuccessful acquisitions or other strategic transactions, the possibility of a decline in the popularity of football or other sports, the Company's ability to expand its fanbase, sponsors and commercial partners, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/211781
FAQ
What is Kraig Biocraft Laboratories producing?
What is the significance of the BAM-1 production phase for KBLB?
How did the spring production trials impact KBLB's plans?
What are the expected outcomes of KBLB's BAM-1 production?
